Theravance to start phase 2b clinical program with beta agonist for asthma

By Lisa Kerner

Erie, Pa., April 20 - Theravance, Inc. said that GlaxoSmithKline has enrolled the first patient in a phase 2b clinical program with the investigational beta agonist (LABA) compound, 159797 ('797) from the Beyond Advair collaboration, in patients with mild to moderate asthma.

As part of the collaboration, the companies plan to develop a once-a-day inhaled combination medicine comprised of a LABA and a corticosteroid.

"We are excited that a compound has moved into the phase 2b program, with two additional compounds, 642444 and 159802, continuing to progress in clinical development," senior vice president, development at Theravance, Michael Kitt, said in a news release.

"The goal is to generate repeat-dose data in a larger number of patients with all three compounds in order to make decisions about further development."

Theravance is a biopharmaceutical company located in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.